Britain and America have hammered out a key commercial pact that will preserve zero duties on UK pharmaceutical exports being sold in the US market.
Agreement Details of the Deal
As part of the deal, the UK has agreed to boost expenditure on medicines through the National Health Service (NHS). This commitment guarantees that import taxes on these vital goods will remain at zero for a duration of 36 months.
This development is in response to previous threats to dramatically increase import taxes on patented drug imports, with increases mentioned up to one hundred percent.
"This deal with the UK reinforces the global environment for new treatments and establishes long-overdue fairness to U.S.–U.K. drug exports," a release noted.
Trade Significance
Drugs represent one of the UK's largest export categories to the United States, which is by far the primary buyer for large companies like GSK and AstraZeneca.
Trade data reveal that in the 12 months leading up to last September, the UK sold drugs totaling £11.1bn to the US. This value represented a significant portion of total UK exports in that timeframe.
"This deal protects jobs, stimulates capital expenditure and sets the stage for the UK to establish itself as a worldwide center for biotech and pharma," a government official commented.
Key NHS Changes
The agreement includes several specific pledges from the British government:
- Higher Cost Ceiling: The UK will increase the price threshold at which it judges new therapies to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a aim to double total public funding on medicines from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Refund Ceiling: The percentage manufacturers must return to the NHS to prevent overspending will be restricted at fifteen percent. In the past, repayments were more than twenty percent.
Recent Tensions
The pact comes amid a protracted row between the pharmaceutical industry and the UK government over drug pricing and NHS adoption.
The disagreement were exacerbated by arguments that American patients were charged a premium for the equivalent treatments than people in the Britain and the EU.
Over the last 18 months, several significant drug company projects in the UK have been halted or cancelled, while substantial investments have been pledged toward projects in the United States.
A senior figure publicly accepted that the NHS had to increase expenditure on treatments, noting that its spending on drugs had decreased as a percentage of its overall budget over the last ten years.
